Interpreting the RAPIDO trial: factors to consider

Affiliations

¹ Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia 19121, Italy. Electronic address: alessandro.pastorino@asl5.liguria.it.
² Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia 19121, Italy.

Comment

Alessandro Pastorino et al. Lancet Oncol. 2021 Mar.

. 2021 Mar;22(3):e89.

doi: 10.1016/S1470-2045(21)00072-3.

¹ Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia 19121, Italy. Electronic address: alessandro.pastorino@asl5.liguria.it.
² Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia 19121, Italy.

No abstract available

Comment in

Interpreting the RAPIDO trial: factors to consider - Authors' reply.
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Bahadoer RR, et al. Lancet Oncol. 2021 Mar;22(3):e90-e91. doi: 10.1016/S1470-2045(21)00087-5. Lancet Oncol. 2021. PMID: 33662297 No abstract available.

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP; RAPIDO collaborative investigators. Bahadoer RR, et al. Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7. Lancet Oncol. 2021. PMID: 33301740 Clinical Trial.